Document is current
Any future updates will be listed below
-
Authors
Case, Nicola T.
Gurr, Sarah J. https://orcid.org/0000-0002-4821-0635
Fisher, Matthew C. https://orcid.org/0000-0002-1862-6402
Blehert, David S. https://orcid.org/0000-0002-1065-9760
Boone, Charles https://orcid.org/0000-0002-3542-6760
Casadevall, Arturo https://orcid.org/0000-0002-9402-9167
Chowdhary, Anuradha https://orcid.org/0000-0002-2028-7462
Cuomo, Christina A. https://orcid.org/0000-0002-5778-960X
Currie, Cameron R.
Denning, David W.
Ene, Iuliana V. https://orcid.org/0000-0002-0390-7084
Fritz-Laylin, Lillian K.
Gerstein, Aleeza C. https://orcid.org/0000-0002-0781-9356
Gow, Neil A. R. https://orcid.org/0000-0002-2776-5850
Gusa, Asiya https://orcid.org/0000-0001-9915-1834
Iliev, Iliyan D. https://orcid.org/0000-0003-0884-9749
James, Timothy Y. https://orcid.org/0000-0002-1123-5986
Jin, Hailing https://orcid.org/0000-0001-5778-5193
Kahmann, Regine https://orcid.org/0000-0001-7779-7837
Klein, Bruce S.
Kronstad, James W.
Ost, Kyla S.
Peay, Kabir G. https://orcid.org/0000-0002-7998-7412
Shapiro, Rebecca S. https://orcid.org/0000-0002-7119-8865
Sheppard, Donald C.
Shlezinger, Neta
Stajich, Jason E. https://orcid.org/0000-0002-7591-0020
Stukenbrock, Eva H.
Taylor, John W. https://orcid.org/0000-0002-5794-7700
Wright, Gerard D. https://orcid.org/0000-0002-9129-7131
Cowen, Leah E. https://orcid.org/0000-0001-5797-0110
Heitman, Joseph https://orcid.org/0000-0001-6369-5995
Segre, Julia A. https://orcid.org/0000-0001-6860-348X
- License Information
-
More Information
Article History
Received: 9 September 2023
Accepted: 18 November 2024
First Online: 5 February 2025
Competing interests
: D.W.D. and family hold founder shares in F2G, a University of Manchester spin-out antifungal discovery company, and share options in TFF Pharma. D.W.D. acts or has recently acted as a consultant to Pulmatrix, Pulmocide, Biosergen, TFF Pharmaceuticals, Pfizer, Omega, Novacyt, Rostra Therapeutics, MucPharm, Mundipharma, Lifemine and Cipla; chairs a Data Review Committee for Pulmocide; and acts as a Phase 1 Medical Monitor for Biosergen. In the past three years, D.W.D. has been paid for talks on behalf of BioRad, Basilea and Pfizer. J.E.S. is a paid consultant for Zymergen, Sincarne and Michroma. L.E.C. is a co-founder of and shareholder in Bright Angel Therapeutics, a platform company for the development of novel antifungal therapeutics, and a Science Advisor for Kapoose Creek, a company that harnesses the therapeutic potential of fungi.
